Sanofi-Aventis Hit With Class Action Lawsuit Over Alleged Deceptive Marketing of Qunol Liquid CoQ10 Supplements

A proposed nationwide class action lawsuit accuses Quten Research Institute and its parent company, Sanofi-Aventis U.S. LLC, of deceptively marketing Qunol Liquid CoQ10 supplements as having “superior absorption” compared to standard CoQ10 products. The 54-page legal complaint alleges that independent product testing completely refutes these high-performance marketing claims, leaving everyday people paying a premium price for ordinary results.

Why Consumers Choose CoQ10 and What Qunol Promises

Coenzyme Q10, commonly referred to as CoQ10, is an essential antioxidant produced naturally within the human body. Medical research shows that maintaining adequate levels of this enzyme plays an integral role in supporting metabolic and cardiovascular health, easing debilitating migraines, and reducing persistent muscle pain. Because your body’s natural production of CoQ10 routinely declines due to standard aging, heart conditions, or the regular use of cholesterol-lowering statin medications, millions of health-conscious individuals across the United States have made CoQ10 one of the most widely consumed dietary supplements on the commercial market.

However, from a biological standpoint, the raw, fat-soluble CoQ10 molecule is notoriously difficult for the human digestive tract to absorb when ingested orally. To stand out from the fierce competition, the manufacturers of Qunol Liquid CoQ10 prominently advertise their supplement as a premium, highly bioavailable alternative. The product’s retail packaging and marketing materials boldly proclaim that it features an advanced, patented formulation providing “superior absorption” compared to regular CoQ10 options. Furthermore, the company explicitly tells consumers that its specialized liquid formula is uniquely capable of completely dissolving in both water and fat, promising a faster and far more efficient delivery system into the human bloodstream.

What Independent Testing Revealed About Qunol Liquid CoQ10

The foundation of this consumer protection lawsuit rests on scientific product testing that directly challenges the corporate claims printed on the bottle. While changing a supplement’s physical formulation—such as systematically decreasing particle size or dispersing active enzymes through stable carrier oils—can theoretically boost absorption, these complex technological methods only function properly if the final product remains physically stable after manufacturing. If the formulation degrades over time on store shelves, the intended health advantages completely vanish before the consumer even takes their first dose.

According to the legal complaint filed in federal court, recent scientific testing of Qunol Liquid CoQ10 revealed significant structural defects in how the supplement holds up over time. The laboratory evaluations confirmed “visible crystallization and agglomeration” of the active CoQ10 molecules inside the liquid mixture. In plain terms, this means the active ingredients are actively clumping together and forming solid crystals instead of remaining perfectly dissolved. Because the formulation fails to maintain its stabilized state, the lawsuit argues that the supplement’s actual bioavailability drops significantly upon ingestion, rendering the company’s premium marketing claims completely false, misleading, and deceptive to the public.

How Deceptive Marketing Hurts Everyday Consumers Financially

When you walk down the supplement aisle or browse online marketplaces, you are forced to rely entirely on the accuracy of front-label packaging statements to make informed decisions for your household’s health. The lawsuit highlights that claims regarding a product’s absorption rate, nutrient delivery, and water solubility are highly material to the average consumer. Everyday people are understandably willing to pay a significantly higher price at checkout for a product that explicitly promises to work better, faster, and more effectively than standard, store-brand alternatives.

The legal complaint asserts that because of the widespread crystallization discovered during testing, Qunol Liquid CoQ10 is structurally “no better than any regular, unsolubilized CoQ10 product” available on the market. By aggressively promoting an unverified absorption advantage, the manufacturers are accused of charging an unjust premium for an ordinary supplement. Plaintiffs argue that if they had known the liquid formula failed to remain dissolved and stable, they would not have purchased the product or would have paid significantly less for it, leaving thousands of shoppers financially harmed by a corporate pattern of exaggeration.

Qunol’s Legal History and Past Injunction Over Similar Claims

This is not the first time the makers of Qunol supplements have faced severe scrutiny from federal authorities and consumer advocacy groups regarding their public marketing representations. The current class action filing brings to light a striking historical pattern of legal trouble, revealing that a federal district court previously intervened to halt similar corporate behavior. Specifically, on March 13, 2013, a strict 10-year judicial injunction was officially entered against Quten Research Institute, legally prohibiting the manufacturer from continuing to advertise that its Qunol products provided six times the absorption rate of competing brands or “regular CoQ10.”

The newly filed complaint points out that the modern iteration of Qunol’s marketing campaign began surfacing shortly after that decade-long legal restriction expired. The plaintiffs argue that rather than permanently correcting their internal corporate practices and sticking to verified science, the defendants “simply repackaged their false claims and have proceeded to sell the same deception” under a slightly altered label. The lawsuit expresses deep frustration with this cyclical pattern, emphasizing that the company has repeatedly shown it cannot abstain from utilizing misleading statements to maximize its commercial profit margins at the expense of regular shoppers.

Growing Legal Scrutiny for the Supplement Manufacturer

The absorption lawsuit joins a growing list of class action complaints targeting the internal manufacturing and labeling practices of Quten Research Institute over the past few years. For instance, on May 24, 2024, the supplement company was hauled back into a court of law when an aggressive consumer filing alleged that the organization significantly misrepresented the total dosage amounts contained in several lines of its CoQ10 and alternative wellness supplements. That case alleged that the front labels displayed high nutritional values that could only actually be achieved if consumers ingested double or triple the standard single-unit serving size.

Additionally, in April 2023, a separate proposed class action lawsuit targeted the company’s specialized mineral division, claiming that the Qunol Extra Strength Magnesium Glycinate supplements actually contained a drastically lower amount of active magnesium than advertised on the packaging. These compounding legal challenges indicate a broader, systematic pattern where the manufacturer is accused of identifying desirable health attributes, advertising them aggressively to capture market share, and charging premium pricing while completely ignoring the underlying chemical reality and scientific metrics of their final shelf products.

Consumer Protection Laws Hold Supplement Brands Accountable

Although the dietary supplement industry is not subjected to the same rigid, pre-market approval processes that the U.S. Food and Drug Administration (FDA) applies to prescription medications, wellness companies are still strictly bound by state and federal false advertising statutes. In this specific litigation, the plaintiffs are seeking protection under powerful legal frameworks, including the California Unfair Competition Law, the California False Advertising Law, the California Consumers Legal Remedies Act, and the New Jersey Consumer Fraud Act. These consumer protection laws exist to ensure that any commercial claim made about a product’s performance must be fully supported by verifiable, reproducible science.

Under these regional laws, when a business uses unverified or flatly disproven claims to sell consumer goods, everyday people have the legal right to band together and demand full financial restitution. The civil court system serves as a vital counterweight against corporate overreach, allowing regular citizens to hold massive wellness conglomerates accountable for the integrity of the statements they print on their labels. By bringing these structural issues to light, class action litigation forces an explicit choice upon corporate boards: either back up your premium marketing claims with undeniable laboratory data or stop misleading the public.

Who May Be Eligible to Join the Qunol Class Action

The newly initiated Qunol Liquid CoQ10 lawsuit was filed by lead plaintiffs Christa Kirby, a resident of New Jersey who purchased the supplement via Amazon for $29.99, and Mark Rivers, a resident of California who bought the product directly from the official website for $29.62. The legal teams represent a proposed nationwide class to ensure that geographic location does not prevent affected consumers from seeking a fair resolution. You may be eligible to participate as a class member if you purchased Qunol Liquid CoQ10 anywhere in the United States for your own personal, direct household consumption rather than for commercial resale or retail distribution.

Because this lawsuit was filed on June 15, 2026, in the U.S. District Court for the District of New Jersey under Case Number 2:26-cv-07123, it is currently in its earliest litigation stages. This means there is no immediate settlement fund available yet, and no official claim forms have been distributed to the public. However, if the court rules in favor of the consumers or if the manufacturers choose to settle the matter out of court to avoid a full jury trial, a financial fund will be created to provide cash refunds to eligible buyers.